BioCentury
ARTICLE | Company News

Alteogen, 3SBio deal

November 9, 2015 8:00 AM UTC

Alteogen granted 3SBio exclusive rights to develop and commercialize ALT-P7 in China, including Hong Kong and Macau. The preclinical antibody-drug conjugate inhibitor of EGFR2 ( HER2; ErbB2; neu) i...